NSRX — Nasus Pharma Ltd

—
NYSE · Health Care · Pharmaceuticals · CIK 2029039 ·
Last close
$2.55
Market Cap
$29.87M
52W High
$9.50
52W Low
$1.98
ADV30
15,896
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 12,449,000 7,818,000 1,453,000
Dec 2025 — — — — 5,004,000 1,237,000 2,236,000
Jun 2025 — — — — 639,000 203,000 4,953,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-24,462,000
Inventory
—
Receivables
—
ST Investments
$4,000,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -4,904,000 -5,856,000 5,004,000 2,236,000 2,768,000 -4,918,000
Dec 2024 0 -1,078,000 -1,532,000 717,000 3,929,000 -3,212,000 -665,000
Dec 2023 0 -1,147,000 -1,051,000 444,000 4,241,000 -3,797,000 -1,029,000
Dec 2022 0 -2,042,000 -1,711,000 417,000 3,202,000 -2,785,000 -1,211,000

Peers — same industry

TickerNameMarket CapLastDaily %
NNVC NANOVIRICIDES, INC. $29.86M $1.17 —
BHST BIOHARVEST SCIENCES INC. $29.92M $1.32 —
ATHE ALTERITY THERAPEUTICS LTD $30.13M $1.65 —
RLFTY MindMaze Therapeutics Holding SA $30.24M $0.18 —
PRRUF IMMUTEP Ltd $29.47M $0.02 —

News headlines (Yahoo Finance, 1h cache)

Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
2026-11-17 13:00 · Yahoo
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
2026-11-16 13:00 · Yahoo
Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
2026-11-10 13:00 · Yahoo
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
2026-09-29 12:00 · Yahoo
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
2026-09-14 12:00 · Yahoo
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
NSRX: First Half 2026 Financial Results
2026-08-21 11:00 · Yahoo
Nasus Pharma Announces Transition of Chief Financial Officer
2026-08-19 11:00 · Yahoo
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
2026-08-17 12:14 · Yahoo
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
2026-07-28 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.